<DOC>
	<DOCNO>NCT02234089</DOCNO>
	<brief_summary>The purpose study detect factor influence decision make treatment pathway hormone-naïve prostate cancer patient without comorbidities receive medicinal androgen deprivation therapy ( Degarelix LHRH agonist ) .</brief_summary>
	<brief_title>Therapy Pathways Treatment Hormone Naïve Prostate Cancer Patients With Without Comorbidities Treated With Degarelix Luteinizing-Hormon-Releasing-Hormon ( LHRH ) Agonists .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Diagnosed Prostate Cancer indicate ADT accord Summary Product Characteristics ( SmPC ) Decision make prescribe ADT ( Degarelix LHRH agonist ) prior enrolment Patient previous currently hormonal management Prostate Cancer , except curative intention , duration neoadjuvant/adjuvant therapy exceed 6 month treatment terminate least 6 month prior baseline . Participation clinical trial baseline followup period</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>